Search results
Results from the WOW.Com Content Network
Total intravenous anesthesia (TIVA) refers to the intravenous administration of anesthetic agents to induce a temporary loss of sensation or awareness. The first study of TIVA was done in 1872 using chloral hydrate , [ 1 ] and the common anesthetic agent propofol was licensed in 1986.
To induce general anesthesia, propofol is the drug used almost exclusively, having largely replaced sodium thiopental. [13]It is often administered as part of an anesthesia maintenance technique called total intravenous anesthesia, using either manually programmed infusion pumps or computer-controlled infusion pumps in a process called target controlled infusion (TCI).
Actavis Generics [1] (formerly known as Watson Pharmaceuticals and Actavis plc, prior to the acquisition of Irish-based Allergan, Inc.) is a global pharmaceutical company focused on acquiring, developing, manufacturing and marketing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products.
Image source: The Motley Fool. Teva Pharmaceutical Industries (NYSE: TEVA) Q4 2024 Earnings Call Jan 29, 2025, 8:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call Participants
A new video game I really wanted at the the time. I chose not to buy it so I could spend the money on her, and she surprised me with it after we had a Valentine's day dinner. #33. Buy a small ...
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Teva Pharmaceutical Industries wasn’t one of them. The 10 ...
In April, Teva offered to acquire Mylan for $40 billion, [41] only a fortnight after Mylan offered to buy Perrigo for $29 billion. [42] Teva's offer for Mylan was contingent on Mylan abandoning its pursuit of Perrigo. [43] Mylan stated in June 2015 that Teva's disclosure that it had a 1.35 percent stake in Mylan violated US antitrust rules. [44]
The R&D group at teva api consists of a team of over 760 top scientists located in 7 development centers worldwide: A large center in Israel (synthetic products and peptides), a large center in Hungary (fermentation and semi-synthetic products), and a facility in India and additional sites in Italy, Croatia, Mexico and the Czech Republic (development of high potency API). teva api's R&D ...